» Articles » PMID: 38974214

IL-1 Receptor Dynamics in Immune Cells: Orchestrating Immune Precision and Balance

Overview
Journal Immune Netw
Date 2024 Jul 8
PMID 38974214
Authors
Affiliations
Soon will be listed here.
Abstract

IL-1, a pleiotropic cytokine with profound effects on various cell types, particularly immune cells, plays a pivotal role in immune responses. The proinflammatory nature of IL-1 necessitates stringent control mechanisms of IL-1-mediated signaling at multiple levels, encompassing transcriptional and translational regulation, precursor processing, as well as the involvement of a receptor accessory protein, a decoy receptor, and a receptor antagonist. In T-cell immunity, IL-1 signaling is crucial during both the priming and effector phases of immune reactions. The fine-tuning of IL-1 signaling hinges upon two distinct receptor types; the functional IL-1 receptor (IL-1R) 1 and the decoy IL-1R2, accompanied by ancillary molecules such as the IL-1R accessory protein (IL-1R3) and IL-1R antagonist. IL-1R1 signaling by IL-1β is critical for the differentiation, expansion, and survival of Th17 cells, essential for defense against extracellular bacteria or fungi, yet implicated in autoimmune disease pathogenesis. Recent investigations emphasize the physiological importance of IL-1R2 expression, particularly in its capacity to modulate IL-1-dependent responses within Tregs. The precise regulation of IL-1R signaling is indispensable for orchestrating appropriate immune responses, as unchecked IL-1 signaling has been implicated in inflammatory disorders, including Th17-mediated autoimmunity. This review provides a thorough exploration of the IL-1R signaling complex and its pivotal roles in immune regulation. Additionally, it highlights recent advancements elucidating the mechanisms governing the expression of IL-1R1 and IL-1R2, underscoring their contributions to fine-tuning IL-1 signaling. Finally, the review briefly touches upon therapeutic strategies targeting IL-1R signaling, with potential clinical applications.

Citing Articles

Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction.

Liu J, Chen M, Li S, Cai L, Ma L, Yang Q Front Immunol. 2024; 15:1458488.

PMID: 39450178 PMC: 11499093. DOI: 10.3389/fimmu.2024.1458488.


Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke.

Matys P, Mironczuk A, Starosz A, Grubczak K, Kochanowicz J, Kulakowska A Int J Mol Sci. 2024; 25(19).

PMID: 39408843 PMC: 11476913. DOI: 10.3390/ijms251910515.

References
1.
Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y . Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008; 9(6):684-91. DOI: 10.1038/ni.1606. View

2.
Pinteaux E, Abdulaal W, Mufazalov I, Humphreys N, Simonsen-Jackson M, Francis S . Cell-specific conditional deletion of interleukin-1 (IL-1) ligands and its receptors: a new toolbox to study the role of IL-1 in health and disease. J Mol Med (Berl). 2020; 98(7):923-930. PMC: 7343756. DOI: 10.1007/s00109-020-01928-5. View

3.
Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

4.
Casadio R, Frigimelica E, Bossu P, Neumann D, Martin M, Tagliabue A . Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett. 2001; 499(1-2):65-8. DOI: 10.1016/s0014-5793(01)02515-7. View

5.
Ouyang W, Kolls J, Zheng Y . The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008; 28(4):454-67. PMC: 3424508. DOI: 10.1016/j.immuni.2008.03.004. View